Physician profile
Lynn Kohlmeier
NPI 1528026820
$517,643.89
in general payments reported to CMS, 2019-2025
10 companies · $166K in 2025
The $166K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81K · 2020: $17K · 2021: $3,684 · 2022: $61K · 2023: $107K · 2024: $82K · 2025: $166K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $258K · Travel and Lodging: $55K · Consulting Fee: $23K · Food and Beverage: $9,610 · Honoraria: $8,950 · Education: $7.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $258,251.69 |
| Travel and Lodging | $55,113.09 |
| Consulting Fee | $22,813.56 |
| Food and Beverage | $9,610.14 |
| Honoraria | $8,950.00 |
| Education | $7.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $176,132.49 | 2022-2025 | Yorvipath |
| Amgen INC. | $171,976.27 | 2019-2025 | Evenity, Prolia, Prolia |
| Radius Health, INC. | $79,339.28 | 2019-2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $51,514.50 | 2019-2025 | Strensiq |
| Shire North American Group INC | $37,487.92 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $681.29 | 2019-2022 | |
| Kyowa Kirin, INC. | $198.84 | 2024 | |
| Baxter Healthcare | $115.46 | 2019 | |
| Lilly USA, LLC | $99.88 | 2019 | |
| Horizon Therapeutics Plc | $97.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Kohlmeier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.